Additionally, S1A-domain represses xylulokinase XYLB, and decreasing of its product (Xu5P) was proposed as one of the potential metabolomics biomarkers of COVID-19 (De Silva et al., 2020; Wu et al., 2020). Here, XYLB is linked to COVID-19.